Skip to main content Accessibility help
  • Print publication year: 2013
  • Online publication date: February 2013

31 - Neuropathologicalassessment

from Section II - Neurobehavioral and Neuropsychiatric Assessment


This chapter focuses on subtle neurological signs (SNS) in schizophrenia and illustrates the principles of their assessment and interpretation among persons with neuropsychiatric disorders more generally. Growing appreciation of the role of SNS has led to the development of multiple, structured instruments to assess neurological impairment. These instruments differ markedly in the specific neurological signs assessed and in their psychometric properties. The most commonly employed neurological scales (The Woods Scale, The Heidelberger Scale, The Modified Quantified Neurological Scale, The Cambridge Neurological Inventory, and The Neurological Evaluation Scale (NES)) and their characteristics are described. NES is among the most widely used SNS scales in schizophrenia research. Schizophrenia and other psychoses are characterized by the presence of psychotic symptoms, which are frequently divided into positive symptoms and negative symptoms. Research on neurological signs provides strong evidence supporting the conceptualization of neurological signs as a trait feature of schizophrenia.


1. FullerGN, KrosJM.Gliomatosis cerebri. In LouisDN, OhgakiH, WiestlerOD, CaveneeWK, editors. WHO Classification of Tumours of the Central Nervous System. Lyon: IARC Press; 2007, pp. 50–2.
2. LantosPL, BrunerJM.Gliomatosis cerebri. In KleihuesP, CaveneeWK, editors. Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC Press; 2000, pp. 92–3.
3. ArtigasJ, Cervos-NavarroJ, IglesiasJR, EbhardtG.Gliomatosis cerebri: clinical and histological findings. Clin Neuropathol. 1985;4(4):135–48.
4. JenningsMT, FrenchmanM, ShehabTet al. Gliomatosis cerebri presenting as intractable epilepsy during early childhood. J Child Neurol. 1995;10(1):37–45.
5. FilleyCM, Kleinschmidt-DeMastersBK, LilleheiKO, DamekDM, HarrisJG.Gliomatosis cerebri: neurobehavioral and neuropathological observations. Cogn Behav Neurol. 2003;16(3):149–59.
6. DeckertM, PaulusW.Malignant lymphomas. In LouisDN, OhgakiH, WiestlerOD, CaveneeWK, editors. WHO Classification of Tumours of the Central Nervous System. Lyon: IARC Press; 2007, pp. 188–92.
7. BakshiR, MazziottaJC, MischelPSet al. Lymphomatosis cerebri presenting as a rapidly progressive dementia: clinical, neuroimaging and pathologic findings. Dement Geriatr Cogn Disord. 1999;10(2):152–7.
8. RollinsKE, Kleinschmidt-DeMastersBK, CorboyJR, DamekDM, FilleyCM.Lymphomatosis cerebri as a cause of white matter dementia. Hum Pathol. 2005;36(3):282–90.
9. WeaverJD, VintersHV, KoretzBet al. Lymphomatosis cerebri presenting as rapidly progressive dementia. Neurologist 2007;13(3):150–3.
10. LewerenzJ, DingX, MatschkeJet al. Dementia and leukoencephalopathy due to lymphomatosis cerebri. J Neurol Neurosurg Psychiatry 2007;78(7):777–8.
11. KanaiR, ShibuyaM, HataTet al. A case of ‘lymphomatosis cerebri’ diagnosed in an early phase and treated by whole brain radiation: case report and literature review. J Neurooncol. 2008;86(1):83–8.
12. MoulignierA, GalicierL, MikolJet al. Primary cerebral lymphoma presenting as diffuse leukoencephalopathy. AIDS 2003;17(7):1111–13.
13. ThurnherMM, RiegerA, Kleibl-PopovCet al. Primary central nervous system lymphoma in AIDS: a wider spectrum of CT and MRI findings. Neuroradiology 2001;43(1):29–35.
14. ProvincialiL, SignorinoM, CeravoloG, PasquiniU.Onset of primary brain T-lymphoma simulating a progressive leukoencephalopathy. Ital J Neurol Sci. 1988;9(4):377–81.
15. CarlsonBA.Rapidly progressive dementia caused by nonenhancing primary lymphoma of the central nervous system. AJNR Am J Neuroradiol. 1996;17(9):1695–7.
16. Ayuso-PeraltaL, Orti-ParejaM, Zurdo-HernandezMet al. Cerebral lymphoma presenting as leukoencephalopathy. J Neurol Neurosurg Psychiatry 2001;71(2):243–6.
17. BodensteinerDC, SkikneB.Central nervous system involvement in mycosis fungoides: diagnosis, treatment and literature review. Cancer 1982;50(6):1181–4.
18. RappaportH, ThomasLB.Mycosis fungoides: the pathology of extracutaneous involvement. Cancer 1974;34(4):1198–229.
19. HallahanD, GriemM, GriemS, DudaE, BaronJ.Mycosis fungoides involving the central nervous system. J Clin Oncol. 1986;4(11):1638–44.
20. MakepeaceAR, Sebag-MontefioreD, SpittleMF, SmithNP.Mycosis fungoides of the central nervous system. J R Soc Med. 1989;82(2):116–17.
21. TacconiL, EcclesS, JohnstonFG, SymonL.Mycosis fungoides with central nervous system involvement – a case report: T-cell lymphoma of the brain. Surg Neurol. 1995;43(4):389–92.
22. VitekJJ, DuvallER.Cranial computed tomography in the tumorous stage of mycosis fungoides. J Comput Assist Tomogr. 1982;6(4):702–5.
23. ConradME, OmuraGA.Mycosis fungoides: carcinogens and cerebral involvement. Am J Med Sci. 1987;293(2):122–4.
24. ZonenshaynM, SharmaS, HymesKet al. Mycosis fungoides metastasizing to the brain parenchyma: case report. Neurosurgery 1998;42(4):933–7.
25. LiN, KimJH, GlusacEJ.Brainstem involvement by mycosis fungoides in a patient with large-cell transformation: a case report and review of literature. J Cutan Pathol. 2003;30(5):326–31.
26. del Carpio-O’DonovanR, FreemanC.Brainstem involvement with mycosis fungoides: an unusual central nervous system complication. Am J Neuroradiol. 2002;23(4):533–4.
27. LallyA, HollowoodK, WhittakerS, TurnerR.Central nervous system involvement in stage 1b mycosis fungoides. Br J Dermatol. 2007;157(4):815–16.
28. AznarAO, MonteroMA, RoviraR, VidalFR.Intravascular large B-cell lymphoma presenting with neurological syndromes: clinicopathologic study. Clin Neuropathol. 2007;26(4):180–6.
29. VierenM, SciotR, RobberechtW.Intravascular lymphomatosis of the brain: a diagnostic problem. Clin Neurol Neurosurg. 1999;101(1):33–6.
30. ChapinJE, DavisLE, KornfeldM, MandlerRN.Neurologic manifestations of intravascular lymphomatosis. Acta Neurol Scand. 1995;91(6):494–9.
31. BeristainX, AzzarelliB.The neurological masquerade of intravascular lymphomatosis. Arch Neurol. 2002;59(3):439–43.
32. SchwarzS, ZoubaaS, KnauthM, SommerC, Storch-HagenlocherB.Intravascular lymphomatosis presenting with a conus medullaris syndrome mimicking disseminated encephalomyelitis. Neuro Oncol. 2002;4(3):187–91.
33. MoussouttasM.Intravascular lymphomatosis presenting as posterior leukoencephalopathy. Arch Neurol. 2002;59(4):640–1.
34. LiewCL, ShyuWC, TsaoWL, LiH.Intravascular lymphomatosis mimicks a cerebral demyelinating disorder. Acta Neurol Taiwan 2006;15(4):264–8.
35. GaulC, HanischF, NeureiterDet al. Intravascular lymphomatosis mimicking disseminated encephalomyelitis and encephalomyelopathy. Clin Neurol Neurosurg. 2006;108(5):486–9.
36. AlbrechtR, KrebsB, ReuscheEet al. Signs of rapidly progressive dementia in a case of intravascular lymphomatosis. Eur Arch Psychiatry Clin Neurosci. 2005;255(4):232–5.
37. FerreriAJ, CampoE, SeymourJFet al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant’. Br J Haematol. 2004;127(2):173–83.
38. GlassJ, HochbergFH, MillerDC.Intravascular lymphomatosis. A systemic disease with neurologic manifestations. Cancer 1993;71(10):3156–64.
39. OssegeLM, PostlerE, PlegerB, MullerKM, MalinJP.Neoplastic cells in the cerebrospinal fluid in intravascular lymphomatosis. J Neurol. 2000;247(8):656–8.
40. PonzoniM, ArrigoniG, GouldVEet al. Lack of CD 29 (beta1 integrin) and CD 54 (ICAM-1) adhesion molecules in intravascular lymphomatosis. Hum Pathol. 2000;31(2):220–6.
41. DiGiuseppeJA, NelsonWG, SeifterEJ, BoitnottJK, MannRB.Intravascular lymphomatosis: a clinicopathologic study of 10 cases and assessment of response to chemotherapy. J Clin Oncol. 1994;12(12):2573–9.